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such events in the light of available evidence and discussion with the treating physi-
cians. Results: A total of 275 patients were included in the study for case review 
as per the study criteria. Out of 275 patients, 150 patients had at least one indicator 
(55%) and detection of adverse events was about 19.2%. Ratio of actual adverse event 
detected to the presence of indicators was calculated as true positives. The average 
true positive value of indictors was 33%. Average number of indicators present per 
patient was determined to be 3.82. The harm categorization was carried out for 
the observed adverse events as per National Coordinating Council for Medication 
Error Reporting and Prevention (NCC MERP). ConClusions: The present study 
showed that indicator tool could be used to review the cases prospectively and 
identify adverse events. The identified indicators showed the pattern and frequency 
of adverse events. Findings of our study supported the idea of making the indicator 
tool as a practical aid for identification of adverse events.
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The pharmaceutical care concept has been popular in the world during past dec-
ades, but it did not reach well to its maturity in some countries, so the investigation 
on barriers to the implementation of the pharmaceutical care in these countries 
would be great of interest. objeCtives: The aim of the study was to identify and 
prioritize barriers to the provision of pharmaceutical care in Iranian community 
pharmacies based on Tehran community pharmacists’ perceptions. Setting The pre-
sent study was conducted with participation of pharmacists working in community 
pharmacies settled in Tehran, the capital city of Iran. Methods: A cross-sectional 
descriptive study was performed using an anonymous questionnaire between 
August and November 2013. 505 community pharmacists expressed their percep-
tions on items by a 5-point Likert-type scale. Besides descriptive analysis, data was 
also analyzed through structural equation modeling. Main outcome measured was the 
importance perceived by community pharmacists in the case of 5 area including 
resources, attitude and vision, education and training, skills, regulatory and environ-
mental issues. Results: Five major dimensions included in the survey instrument 
were confirmed by confirmatory factor analysis. According to the model developed 
based on pharmacists’ opinions, lack of pharmacists’ skills and lack of appropriate 
regulation and environment are the two most important barriers of the provision of 
pharmaceutical care, and the least important is lack of resources. ConClusions: 
Findings of the present study showed that importance of various barriers vary from 
country to country based on the pharmacists’ perceptions, and corrective actions 
should be made accordingly.
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objeCtives: MediGuide technology is designed to monitor the position of diagnos-
tic and therapeutic catheters equipped with a sensor MediGuide and navigation in 
vascular or cardiac intervention in the environment of electro-physiological labora-
tory. MediGuide compared to conventional technology, offers the 3D display on the 
live fluoroscopy or recorded background, radiation burden reduction, fluoroscopy 
time and total time performance. The aim of this thesis is to analyze the clini-
cal and cost effectiveness of new technologies MediGuide in the Czech Republic. 
Results of the analysis are being compared to the studies of the German Cardiac 
where technology is positively evaluated. Methods: The evaluation method is 
cost-effectiveness analysis, which compares technology system MediGuide to a 
comparator angiography Siemens Artis Zee. Value of the effect was determined by 
TOPSIS in which they were entered weight values obtained by Saaty method of pair 
comparison by group of experts. The sum of direct costs includes costs associated 
with the operation of both technologies. Calculated values of costs and effects were 
achieved in incremental ICER assessment ratio, fixing the amount of costs per unit of 
effect. Results: More appreciated criteria in Saaty method were: safety and effec-
tiveness of the technology. The fundamental values of the following criteria in this 
method were used: radiation burden, which in the Czech Republic reached values 
using conventional technology 575±511μ Gy. m2 and in Germany 14,453±7,403μ Gy. 
m2, fluoroscopy time values for Czech Republic 7.5±4.5min; Germany 34±9min and 
total time performance of Czech Republic 148±91 min; Germany 157±51min. The 
cost of power at the treatment of 100 patients was in the first year to CZK 181,711; 
MediGuide under the same conditions CZK 276,765. ConClusions: Manufacturer 
of MediGuide values technology as an effective, safe and value-added reduce the 
radiation burden of the patient, fluoroscopy time and shorten the overall time per-
formance.
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objeCtives: Gaining reimbursement is a complex process that involves gener-
ating the right evidence and communicating it successfully to stakeholders. To 
ensure alignment of the value story across countries and help affiliates in their 
local submissions, headquarters (HQ) develop the global value dossier (GVD). We 
have investigated whether the current GVD meets HQ and local affiliates (LAF) 
expectations. Methods: Pharma HEOR and market access professionals from HQ 
and LAF were invited to participate in telephone interviews to assess their views 
on current use and utility of the GVD. Results were analyzed to identify differences 
and alignments between HQ and LAF. Results: 43 [16HQ/27LAF] professionals were 
invited; 22 [8HQ/14LAF] tentatively agreed to participate and 15 [7HQ/8LAF] were 
finally interviewed. Compared to LAF, HQ perceive the GVD more useful (HQ: 100%; 
LAF:63%) and capable of positively influencing the final outcome of submissions 
(HQ:86%; LAF:50%). Compared to HQ, LAF consider the GVD is delivered too late 
(LAF:88%; HQ:13%) and that LAF should be involved in GVD development (LAF:100%; 
HQ:71% but only for review). HQ consider that LAF involvement should be restricted 
to the GVD review while LAF think they should participate in building the value 
story (63%) or the economic model (37%). LAF prefer a modular GVD with each 
component delivered separately (LAF: 88%; HQ: 66%), request national data to be 
included (LAF:63%; HQ:14%), and cannot see the utility of new technologies for the 
GVD (LAF:75%; HQ:33%). HQ and LAF expect the GVD to be updated continuously 
(HQ:6%; LAF:75%) and be supplemented with phase IIIb data for potential resubmis-
sions (HQ:100%; LAF:88%). ConClusions: HQ and LAF expectations differ particu-
larly on how soon the GVD should be made available, the involvement of affiliates 
during its development and the applicability of the GVD contents to local submis-
sions. How to address these discrepancies to ensure alignment will be discussed.
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objeCtives: In German hospitals there is a need for optimized crisis- and risk 
management. About one third of all hospital-acquired patient damages are due to 
medication errors. The aim of our interdisciplinary project “Risk Management in 
Hospitals” is to analyze the behavior of the various key players in the fields of medi-
cal care, human resources, supply and IT-systems in the context of various simu-
lated risk scenarios as well as to develop adequate risk management tools. In this 
abstract, the first results on medication errors are presented. Methods: Through 
a network of experts, systematic literature searches and expert workshops, the five 
most relevant crises from different disciplines (medical, HR, supply and IT) were 
identified and specified. In a standardized survey among German hospital managers 
further data were collected on these crises, their management and influencing fac-
tors. The results on medication errors presented here are based on the survey data 
using a linear regression model. Results: The analysis was based on fully com-
pleted questionnaires by 97 German hospitals. 70% of the hospitals reported that 
crises due to medical errors occurred in the last 5 years, which could not be handled 
with established risk management tools. Although the crisis-appearance was lower 
in private hospitals (28%) compared to publicly funded (31%) and nonprofit (41%) 
hospitals, this difference was not significant. We recognized that a high frequency 
in the occurrence of medical errors was significantly associated with a lower evalu-
ation of risk management issues (e.g. the presence of a staff member responsible 
for risk management, scenario analysis and crises trainings). ConClusions: Our 
study confirms that German hospitals have to expand their targeted risk man-
agement activities in order to prevent the occurrence of hospital crises especially 
due to medical and medication errors. All survey results will be incorporated in a 
decision-making and benchmarking-tool for hospital managers to improve crisis 
management in German hospitals.
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objeCtives: A Budget Impact Analysis (BIA) analyses the financial consequence 
associated with the uptake of a new treatment option in the market; which can 
impact planning and forecasting and influence changes to pharmaceutical and 
health care budgets. Therefore, BIA forms a key consideration of the Dutch Health 
Care Insurance Board (ZiNL) when making a reimbursement decision regarding a 
new treatment intervention. The current analysis investigates consistent trends 
observed between the predicted budget versus the actual budget spent on reim-
bursed drugs in the Netherlands. Methods: Forecasted data specific to new drugs 
reimbursed under list 1B between 2009 and 2013 were extracted from drug reim-
bursement reports available from the ZiNL website. Actual data of the selected drugs 
were extracted from the Drug and medical devices Information Project database 
(GIP database). Per year and cumulative (between 1 and 5 years) data on total drug 
cost, total number of users and total cost per patient were compared between the 
forecasted values and the actual values. Results: In total 20 drugs were included in 
the analysis, of which 12 presented data for 3 years or more. Compared to the actual 
data, the expected total drug cost was overestimated for 14 drugs, total number of 
users was overestimated for 12 drugs and for 10 drugs the total cost per patient was 
overestimated. Total number of users was most accurately estimated, presenting a 
pooled cumulative overestimation of 5 times the actual number of users. Total drug 
cost was least accurately estimated (pooled cumulative overestimation of 13 times 
the actual total cost), since the total drug cost includes the uncertainty reflected 
in both the total number of users and total cost per patient. ConClusions: The 
expected budget of 1B drugs in reimbursement submission reports generally over-
estimated the actual budget presented in the GIP database between 2009 and 2013.
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objeCtives: Budget impact analyses are an essential component in the economic 
evaluation of new drugs. These analyses allow the health care payer to assess the 
likely impact of the drug on the payer’s budget, and to plan for short- and long- term 
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resource allocation. The objective of this study is to compare the company-predicted 
budget impact with the actual budget impact of high-cost drugs reimbursed in 
Ireland. Methods: All drugs submitted to the health service executive (HSE, health 
care payer in Ireland) for reimbursement under the high-tech drug scheme (a scheme 
used to administer high cost drugs) from 2009 to 2012 were included in the review. 
Company estimates of the likely budget impact of the drug in 2013 were extracted 
from submissions and compared with actual expenditure in 2013 from the health ser-
vice executive-primary care reimbursement service (HSE-PCRS). Only drugs for which 
budget impact estimates were available and which were reimbursed by the HSE in 
2013 were included in the analysis. Results: Ten drugs were included in the analysis, 
including six cancer drugs, two immunomodulators for multiple sclerosis and rheu-
matoid arthritis, and two orphan drugs for cystic fibrosis and idiopathic thrombocyto-
penic purpura. The cumulative expenditure on these drugs in 2013 was € 55.8 million 
compared with a predicted gross budget impact of € 53.4 million, representing a € 2.4 
million underestimate in company submissions. The most significant underestimate 
related to the drug for multiple sclerosis (€ 3.4 million) while the biggest overestimate 
related to the orphan drug for cystic fibrosis (€ 2.9 million). ConClusions: Company 
submissions have been shown to both under- and over-estimate budget impact pre-
dictions. It is important that budget impact estimates are as realistic as possible 
in order to effectively inform decisions on resource allocation or reimbursement.
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objeCtives: The dynamic of the reimbursement politics shows a very differ-
ent pattern in different countries. The REDEL study examined the elapsed time 
from marketing authorization to the starting date of reimbursement of the origi-
nal medicines in Central and Eastern European Countries (Austria, Bulgaria, the 
Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and 
Slovenia). Methods: The basis of comparison were 216 products and their ATC 
codes selected from the database of the European Medicines Agency which were 
granted a marketing authorization between 1st January 2007 and 1st July 2013. In 
the case of these products the research studied the dates, when countries adopted 
them into their reimbursement system. The adoption was the subject of the study 
between 1st January 2010 and 1st July 2013. The following three different indicators 
were calculated in the study: REDEL - the delay between marketing authorization 
date and reimbursement date; INNREIMB - the number of reimbursed INNs accord-
ing to a specific country or MAH; SR - Success Rate as the ratio of reimbursed 
INNs to examined INNs. Results: While an average of 403 days elapsed between 
the authorization and the starting date of reimbursement in Slovenia (mean of 76 
products), the same period was 1295 days in Poland (mean of 21 adoptions). The 
average is 632 days. The top three in the ranking of REDEL of active substances 
(ATC 1st level – anatomical main group) were dermatologicals (D), respiratory sys-
tem (R) and Muscolo-skeletal system (M). ConClusions: The results show that 
even threefold differences exist among the studied countries with regards to the 
reimbursement delay. An average of almost two years elapse until a producer can 
have the given product adopted into the reimbursement system in a country (the 
REDEL steadily increasing in the studied period, while the number of reimbursed 
products decreasing).
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objeCtives: Price negotiations of a pharmaceutical company with the German 
GKV-Spitzenverband (Association of Statutory Health Insurance) after early ben-
efit assessments can be considered a black box. This analysis aims at providing 
insights on the parameters that drive the final rebate to predict future pricing 
decisions and to enhance the negotiation strategy and therefore secure optimal 
pricing. Methods: Published benefit assessments from the G-BA (Federal Joint 
Committee) website and the products’ prices as listed in the German pharmacy 
selling system were used as a basis for research. The latter allows a comparison of 
launch prices (manufacturer selling prices) and prices after the negotiation with 
the GKV-Spitzenverband (reimbursement prices). The following parameters were 
analyzed: Rebate size, rebate by added benefit rating, and rebate by therapeutic 
area. Results: By June 2014, 36 products had been through price negotiation, with 
the rebate of the launch price ranging from 5-71% (average: 25%). The rebate of prod-
ucts with considerable benefit rating ranged from 10-35% (average: 21%). Products 
with minor added benefit reached rebates between 5-48% averaging at 23%. Products 
with no quantifiable benefit yielded rebates ranging from 11-44% (average: 24%). 
Products with no additional benefit had a rebate between 5-71% averaging at 27%. 
Products in oncology yielded an average rebate of 27%., followed by endocrinology 
(23%), central nervous system (22%), cardiovascular (21%), and infectious diseases 
(16%). ConClusions: The better the added benefit rating of a product, the lower 
is its negotiated rebate. However, only marginal average differences were observed. 
The rebate per therapeutic area did not reveal obvious patterns: Assessments for 
oncology products resulted in above average rebates, while rebates for products for 
infectious diseases were far below the average.
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objeCtives: Regulatory authorities such as the European Medicines Agency 
(EMA) can make marketing authorisation contingent upon post-authorisation 
measures (PAMs) so as to fill in information gaps in efficacy and safety. 
PAMs are generally formulated in agreement with manufacturers, and evalu-
ate clinical hypotheses in an ethical and practical way. In Germany, novel 
medicines must also undergo an early benefit assessment (EBA) by the Federal 
Joint Committee (G-BA) following marketing authorisation. G-BA may demand 
additional evidence in order to formulate an opinion on added therapeutic 
value, which then leads to determination of reimbursement. We compared 
selected PAMs with the corresponding G-BA demands to see if they were sim-
ilar. Methods: Medicines that received a restricted EBA from G-BA before 15 
June 2014 were evaluated and compared with their marketing authorisations by 
EMA. PAMs from EMA, and EBA restrictions from G-BA, were assessed in terms 
of their required additional evidence. Results: Twenty-eight percent of all 79 
medicines assessed by G-BA received a restricted EBA. Only nine of those had 
obligations for PAMs. Four of these were conditional approvals or approval under 
exceptional circumstances, while five received unconditional marketing authori-
sation. G-BA justified restricted EBAs for the four conditional approvals based 
upon agreement with the EMA opinion. For the five unconditional approvals, 
G-BA required considerably more information than EMA. The additional evidence 
requested by the two bodies rarely corresponded to one another. EBA restric-
tions were more influenced by transferability to the German health care context, 
choice of subgroups and appropriate comparator, than were the corresponding 
EMA PAMs. ConClusions: G-BA often demands more evidence than specified 
in EMA PAMs from medicines granted unconditional approval. Although PAMs 
are discussed and agreed between EMA and manufacturers, G-BA demands and 
restrictions are not. The possibility for such discussions with G-BA would be an 
improvement for the future.
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objeCtives: Country-specific lists of standard costs can reduce the variability of 
results in health economic evaluations that are attributed to differences in employed 
data sources and approaches for defining the resource use and unit prices. Moreover 
they potentially speed up the conduct of health economic evaluations. We aim to 
investigate which HTA agency officially recognizes and applies a standard cost list 
and, where such list exists, explore pre-specified procedural and methodological 
aspects. Methods: Reviewing all national pharmacoeconomic guidelines published 
on the ISPOR Website http://www.ispor.org/PEguidelines/index.asp in English (i.e., 30 
out of 37). Standard cost lists mentioned in the guidelines were, inter alia, compared on 
the following aspects: i) objective, ii) authorship, iii) release interval, iv) data sources, 
v) costing perspective, vi) cost categories, and vii) health-state costing. Results: Out 
of the 30 pharmacoeconomic guidelines available in English, a standard cost list was 
officially recognized and applied by 4 HTA agencies (Canada, England, Australia and 
the Netherlands). All 4 lists aim to reduce heterogeneity between health economic 
evaluations in order to increase the comparability. Compiling the standard cost lists 
was commissioned to external scientific institutions in all 4 countries. Updates of the 
lists have been published periodically, spanning from anually (e.g. England) to when 
required for methodological reasons or to ensure currency (e.g. the Netherlands). 
Data collection was primarily based on claims data and/or official statistics; in the 
Netherlands, published research and expert opinions can be employed (for estimating 
resource use). Costs were derived from a payer perspective. Both direct and indirect 
costs were stated, except for Australia (only direct costs). No country presented costs 
in relation to health states. ConClusions: Standard cost lists are mentioned in 
13% of the pharmacoeconomic guidelines available in English. The 4 lists conicide 
on many procedural and methodological aspects. Heterogeneity arises mainly from 
country-specific costs.
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objeCtives: Examine the time between regulatory approval and launch/pricing and 
reimbursement (P&R) approval in the US and EU5 countries.  Methods: Examined 
new molecular entities, formulations and combinations with EMA approval between 
Jan 2009 and May 2014.  Additional analysis of products launched between April 2013 
and May 2014. Time comparison for general medicines vs. orphan/oncology indica-
tions was made including shifts over time.  Data gathered from: USA: FDA approval 
date, wholesale; acquisition cost effective date; UK/Germany: Product availability/
introduction; France: P&R decision (Agrément collectivités/date published in Journal 
Officiel); Italy: First Official Gazette P&R Decree publication; and Spain: Date of 
commercialization. Results: Overall, for launches between Jan 2009 and May 2014, 
the average time from FDA approval to US launch was 6 weeks (oncology 4 weeks; 
orphan drugs 2 weeks). Across the EU5, Germany remains the fastest to market. 
Analysis of new products launched between April 2013 and May 2014 shows time 
to access in Spain has increased vs. the previous 5 years (75 vs. 54 weeks). Limited 
numbers of orphan drugs have completed full Spanish P&R process with 106 weeks 
to launch far exceeding all drugs (75 weeks). Italian average time to complete P&R is 
69 weeks, while average time to be listed in class C-nn, without national reimburse-
ment, is only 18 weeks. UK average time to oncology launch appears short (16 vs. 
20 weeks), however HTA assessments often mean significant access delays. French 
orphan drugs assessment is faster vs. all drugs (46 vs. 50 weeks). ConClusions: 
The time to P&R post-regulatory approval increased ~3 weeks in Italy and ~21 weeks 
in Spain for products launched in the latest year vs. all drugs with EMA approvals 
between Jan 2009 and Dec 2013. 
